2017-02-17,Theravance Biopharma Presents Positive Clinical Data On TD-1473 At The 12th Congress Of The European Crohn's And Colitis Organization
2017-02-15,Theravance Biopharma To Report Fourth Quarter And Full Year 2016 Financial Results On February 27, 2017
2017-02-13,Theravance Biopharma Reaches Analyst Target Price
2017-02-02,Theravance Biopharma To Present At The Leerink Partners 6th Annual Global Healthcare Conference
2017-01-23,Theravance Biopharma Reports New Data From Ongoing TOUR™ Observational Patient Registry In Oral Presentation At SCCM Critical Care Congress
2016-12-19,Theravance Biopharma Highlights Initiation Of Phase 3 Study Of The Closed Triple In Patients With Asthma By GlaxoSmithKline And Innoviva
2016-12-12,Theravance Biopharma Reaches Analyst Target Price
2016-12-06,Theravance Biopharma Receives FDA Fast Track Designation For Velusetrag (TD-5108) For Idiopathic And Diabetic Gastroparesis
2016-12-05,Theravance Biopharma Highlights Filing Of EU Regulatory Submission For The Closed Triple In COPD By GlaxoSmithKline And Innoviva
2016-11-28,Short Interest In Theravance Biopharma Increases 60.2%
2016-11-22,Theravance Biopharma To Present At The 28th Annual Piper Jaffray Healthcare Conference
2016-11-21,Theravance Biopharma Highlights Filing Of U.S. New Drug Application For The Closed Triple In COPD By GlaxoSmithKline And Innoviva
2016-11-18,Ratings Changes Today
2016-11-11,TBPH Crosses Above Average Analyst Target
2016-11-01,Theravance Biopharma To Report Third Quarter 2016 Financial Results On November 8, 2016
2016-11-01,New Data For VIBATIV® (telavancin) Reported In Presentations At IDWeek™ 2016
2016-10-31,Theravance Biopharma Presents Interim Data From Ongoing Telavancin Observational Use Registry (TOUR™) At IDWeek™ 2016
2016-10-28,Theravance Biopharma Announces Pricing Of Public Offerings Of 3,850,000 Ordinary Shares And $200 Million Of 3.25% Convertible Senior Notes Due 2023
2016-10-26,Theravance Biopharma Announces Proposed Public Offerings Of $100 Million Of Ordinary Shares And $150 Million Of Convertible Senior Notes
2016-10-25,Theravance Biopharma Announces Positive Results Including Biomarker Data From Phase 1 Multiple-Ascending Dose Study Of TD-0714, An Inhibitor Of Neprilysin (NEP)
2016-10-20,Theravance Biopharma And Mylan Announce Positive Results From Two Pivotal Phase 3 Studies Of Revefenacin (TD-4208) For The Treatment Of Chronic Obstructive Pulmonary Disease (COPD)
2016-08-01,TBPH Crosses Above Average Analyst Target
2016-06-08,Takeda Licenses Global Rights To Theravance Biopharma's TD-8954, A Novel 5-HT4 Agonist And Motility Agent For Gastrointestinal Motility Disorders
2016-05-02,Short Interest In Theravance Biopharma Decreases By 11.6%
2016-04-28,Commit To Purchase Theravance Biopharma At $17.50, Earn 13% Annualized Using Options
2016-03-22,Ratings Changes Today
2016-01-28,Commit To Buy Theravance Biopharma At $12.50, Earn 14.5% Annualized Using Options
2016-01-11,Theravance Biopharma Becomes Oversold (TBPH)
2015-12-18,Ratings Changes Today
2015-11-05,Ratings Changes Today
2015-11-04,Commit To Buy Theravance Biopharma At $12.50, Earn 12.9% Annualized Using Options
2015-11-03,Theravance Biopharma (TBPH) Stock Boasts a 35% Upside
2015-09-14,Theravance Biopharma And Mylan Initiate Phase 3 Program For Revefenacin (TD-4208) For Treatment Of Chronic Obstructive Pulmonary Disease (COPD)
2015-08-06,Commit To Purchase Theravance Biopharma At $10, Earn 16.2% Annualized Using Options
2015-06-17,Ratings Changes Today
2015-05-07,Commit To Buy Theravance Biopharma At $12.50, Earn 21.8% Annualized Using Options
2015-02-02,Theravance Biopharma, Inc. And Mylan Partner To Develop And Commercialize A Novel LAMA Compound, TD-4208, For COPD
,
,
,
,
